Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

被引:1
|
作者
Silberg, Matteo [2 ]
Krabbe, Laura-Maria [3 ]
Boegemann, Martin [1 ]
Schrader, Andres Jan [1 ]
Tully, Karl [2 ]
Schlack, Katrin [1 ]
机构
[1] Univ Hosp Muenster, Dept Urol, Munster, Germany
[2] Ruhr Univ Bochum, Univ Hosp, Marien Hosp Herne, Dept Urol, Hoelkeskampring 40, D-44625 Herne, Germany
[3] Vivantes Network Hlth, Dept Urol, Berlin, Germany
关键词
CRITERIA;
D O I
10.1016/j.clgc.2024.102164
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Different combination therapies using anti - PD-1 / PD-L1 or CTLA-4 immune checkpoint inhibition (ICI) are widely used in patients with metastatic renal cell carcinoma (mRCC). In the absents of established biomarkers, immune-related adverse events (irAEs) have been discussed as potential predictors of response. Methods In this retrospective cohort study, data of 134 patients with mRCC undergoing ICI treatment (Nivolumab, Ipilimumab and Nivolumab, Pembrolizumab and Axitinib or Avelumab and Axitinib) between 2015 and 2021 were analyzed. To examine the utility of irAEs as predictors of overall survival (OS) and progression-free survival (PFS), separate Kaplan-Meier analyses and Cox proportional regression analyses were applied. Landmark analysis was conducted after 12 weeks to reduce immortal time bias. Result irAEs were observed in 85 patients (63.4%). Cutaneous (n = 52, 38.8%), endocrine (n = 33, 24.6%) and hepatic (n = 19, 14.2%) irAEs were most commonly observed. In Kaplan-Meier analysis, patients experiencing irAEs showed favorable median PFS (15 months, 95% CI, 9.91-20.09) compared to the non-irAE group (5 months, 95% CI, 3.56-6.44, P < .001). The median OS was 25 months (95% CI, 16.79-33.21) in the non-irAE group, while it was not reached in the irAE group (P = .002). In multivariable analysis, the presence of any irAE was associated with favorable PFS (HR 0.46 [95% CI, 0.26-0.82] P = .008) and OS (HR: 0.28 [95% CI, 0.12-0.63] P = .002), respectively. Landmark analysis after 12 weeks showed mixed results depending on the classification of the irAE group at the landmark time. Conclusion The presence of irAEs under ICI therapy in patients with mRCC is associated with better PFS and OS. Thus, manageable irAEs should not be cause for premature discontinuation of ICI therapy, as they seem to indicate favorable outcomes. Considering the time-dependent nature of irAEs is crucial estimating their value as predictive markers.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
    Klein, Brittany A.
    Alves, Fabio Abreu
    de Santana Rodrigues Velho, Julia
    Vacharotayangul, Piamkamon
    Hanna, Glenn J.
    LeBoeuf, Nicole R.
    Shazib, Muhammad Ali
    Villa, Alessandro
    Woo, Sook-Bin
    Sroussi, Herve
    Sonis, Stephen
    Treister, Nathaniel S.
    ORAL DISEASES, 2022, 28 (01) : 9 - 22
  • [32] Delayed immune-related adverse events in patients with advanced melanoma treated with immune checkpoint inhibitors
    Angeles, Arkhjamil
    Sonke, Eric
    Thao Phuong Nguyen
    Bahl, Gaurav
    Poon, Vincent Isaac
    Bernstein, Vanessa
    Weppler, Alison Margaret
    Savage, Kerry J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
    Lee, David J.
    Lee, Howard J., Jr.
    Farmer, Jocelyn R.
    Reynolds, Kerry L.
    CURRENT CARDIOLOGY REPORTS, 2021, 23 (08)
  • [34] Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors
    David J. Lee
    Howard J. Lee
    Jocelyn R. Farmer
    Kerry L. Reynolds
    Current Cardiology Reports, 2021, 23
  • [35] Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors
    Gault, A.
    Anderson, A. E.
    Plummer, R.
    Stewart, C.
    Pratt, A. G.
    Rajan, N.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 263 - 271
  • [36] Immune-related adverse events of checkpoint inhibitors
    Ramos-Casals, Manuel
    Brahmer, Julie R.
    Callahan, Margaret K.
    Flores-Chavez, Alejandro
    Keegan, Niamh
    Khamashta, Munther A.
    Lambotte, Olivier
    Marlette, Xavier
    Prat, Aleix
    Suarez-Almazor, Maria E.
    NATURE REVIEWS DISEASE PRIMERS, 2020, 6 (01)
  • [37] Immune-related adverse events of checkpoint inhibitors
    Manuel Ramos-Casals
    Julie R. Brahmer
    Margaret K. Callahan
    Alejandra Flores-Chávez
    Niamh Keegan
    Munther A. Khamashta
    Olivier Lambotte
    Xavier Mariette
    Aleix Prat
    Maria E. Suárez-Almazor
    Nature Reviews Disease Primers, 6
  • [39] Biomarkers to predict immune-related adverse events with checkpoint inhibitors.
    Head, Lia
    Gorden, Nicholas
    Van Gulick, Robert
    Amato, Carol M.
    Frazer-Abel, Ashley
    Robinson, William
    Holers, V. Michael
    Messersmith, Wells A.
    Davis, S. Lindsey
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [40] Immune-Related Adverse Events From Immune Checkpoint Inhibitors
    Marrone, K. A.
    Ying, W.
    Naidoo, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (03) : 242 - 251